Postmenopausal breast cancer: A best endocrine strategy?

The Lancet

Volumn 386, Issue 10001, 2015, Pages 1317-1319

  Mayer, Erica L ^a   Burstein, Harold J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BODY MASS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; INAPPROPRIATE PRESCRIBING; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); NOTE; OVERALL SURVIVAL; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; TREATMENT DURATION; TUMOR VOLUME; BREAST NEOPLASMS; FEMALE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; TAMOXIFEN;

EID: 84944170483     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)61206-5     Document Type: Note

References (15)

1. Early Breast Cancer Trialists' Collaborative Group Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 2015 published online July 24. http://dx.doi.org/10.1016/S0140-6736(15)61074-1
2. J Cuzick, I Sestak, M Baum et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Lancet Oncol 11 2010 1135 1141
3. MM Regan, P Neven, A Giobbie-Hurder et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up Lancet Oncol 12 2011 1101 1108
4. CJ Van de Velde, D Rea, C Seynaeve et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial Lancet 377 2011 321 331
5. HJ Burstein, AA Prestrud, J Seidenfeld et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor positive breast cancer J Clin Oncol 28 2010 3784 3796
6. AS Coates, EP Winer, A Goldhirsh et al. Tailoring therapies - improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015 Ann Oncol 2015 10.1093/annonc/mdv221 published online May 4.
7. National Comprehensive Cancer Network Breast cancer guidelines http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf 2015 (accessed June 26, 2015).
8. C Davies, H Pan, J Godwin et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
9. PE Goss, JN Ingle, S Martino et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 16 2005 707 715
10. I Sestak, M Dowsett, L Zabaglo et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer J Natl Cancer Inst 105 2013 1504 1511
11. G Viale, MM Regan, P Dell'Orto et al. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial Ann Oncol 22 2011 2201 2207
12. M Gnant, B Mlineritsch, W Schippinger et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679 691
13. PA Francis, MM Regan, GF Fleming et al. Adjuvant ovarian suppression in premenopausal breast cancer N Engl J Med 372 2015 436 446
14. EJ Aiello Bowles, DM Boudreau, J Chubak et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer J Oncol Pract 8 2012 149 157
15. P Hadji, C Jackisch, W Bolten et al. COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy Ann Oncol 25 2014 372 377